leadf
logo-loader
viewAlgernon Pharmaceuticals Inc.
(
CSE:AGNOTCQB:AGNPF
)

Algernon Pharmaceuticals targets first human study for its DMT stroke program in 4Q 2021

The Phase 1 study will investigate the safety, tolerability and pharmacokinetics of intravenous DMT infusion in healthy volunteers with no prior history of psychedelic exposure

Algernon Pharmaceuticals Inc. - Algernon Pharmaceuticals Inc targets first human study for its DMT stroke program for 4Q 2021
Specifically, the trial will aim to identify a sub-hallucinogenic dosing regimen to support planned clinical studies in stroke patients

Algernon Pharmaceuticals Inc (CSE:AGN) (FRA:AGW) (OTCQB:AGNPF) has announced that all of the required permits and licenses for the manufacture of its AP-188 (N, N-Dimethyltryptamine or DMT) have been received. 

As a result, the company said it is targeting its Phase 1 human study to be conducted at Hammersmith Medicines Research in the UK in the fourth quarter of 2021. 

Algernon said it awarded the contract to manufacture the active pharmaceutical ingredient and finished product for its formulation of DMT to Canada-based Dalton Pharma Services. 

READ: Algernon Pharmaceuticals expands Ifenprodil research to pancreatic cancer in new clinical study

The Vancouver-based company said the planned Phase 1 study will investigate the safety, tolerability, and pharmacokinetics of intravenous DMT infusion in healthy volunteers with no prior history of psychedelic exposure. Specifically, the trial will aim to identify a sub-hallucinogenic dosing regimen to support planned clinical studies in stroke patients.

Meanwhile, Algernon also announced that its first preclinical study with research-grade DMT is now underway with Charles River Laboratories. The site in Kuopio, Finland is recognized as a world leader for preclinical stroke studies.

The company said the in vitro experiments will provide information on the duration and dose of infusion needed to achieve maximal cortical neurite outgrowth as well as the underlying mechanism of the drug’s action. These experiments will also inform the design of confirmatory animal stroke studies also planned at Charles River and scheduled for later this year. 

“While there are many companies that are working in or attempting to enter the psychedelic drug space, many are a considerable distance from human studies,” said Algernon CEO Christopher Moreau in a statement. “We announced that we plan to be the first company globally to investigate DMT for stroke and that is a goal that we are getting closer to achieving.”

Algernon has filed provisional patents for new forms of DMT, in addition to formulation, dosage, and method of use claims for ischemic stroke. The company has also filed claims for combination therapy of DMT and Constraint-Induced Movement Therapy.

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

Quick facts: Algernon Pharmaceuticals Inc.

Follow
CSE:AGN

Price: 0.09 CAD

Market Cap: $15.07 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Algernon Pharmaceutical’s preclinical study of DMT for stroke confirms...

Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to share news the company has confirmed in a preclinical study, that increased the growth of cortical neurons by 40% with statistical significance in one arm of the study. That was achieved with a sub...

2 weeks ago

2 min read